Skip to content

BIOSPECIFICS TECHNOLOGIES CORP: 10-K filed 2015-03-16

What BIOSPECIFICS TECHNOLOGIES CORP reported in its annual report filed 2015-03-16 (fiscal FY 2014): 30 published measures, 115 facts as tagged in accession 0001140361-15-011871.

This filing

Form
10-K (annual report)
Filed
2015-03-16
Fiscal period
fiscal FY 2014
Accession
0001140361-15-011871 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BIOSPECIFICS TECHNOLOGIES CORP filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2014-12-3131,026,824USD
At 2013-12-3123,252,244USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2014-12-3130,256,855USD
At 2013-12-3122,332,439USD
At 2012-12-3117,458,346USD
At 2011-12-3114,872,314USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2014-12-319,810,816USD
At 2013-12-315,624,860USD
At 2012-12-313,383,737USD
At 2011-12-313,196,831USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2014-10-01 to 2014-12-311,919,242USD92
2014-01-01 to 2014-12-314,645,960USD365
2014-07-01 to 2014-09-301,394,763USD92
2014-04-01 to 2014-06-30577,966USD91
2014-01-01 to 2014-03-31753,989USD90
2013-10-01 to 2013-12-311,725,802USD92
2013-01-01 to 2013-12-315,285,847USD365
2013-07-01 to 2013-09-301,178,775USD92
2013-04-01 to 2013-06-301,028,186USD91
2013-01-01 to 2013-03-311,353,084USD90
2012-01-01 to 2012-12-312,981,075USD366

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2014-12-319,620,978USD
At 2013-12-314,975,018USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2014-01-01 to 2014-12-316,477,457shares365
2013-01-01 to 2013-12-316,345,615shares365
2012-01-01 to 2012-12-316,351,245shares366

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2014-01-01 to 2014-12-317,079,570shares365
2013-01-01 to 2013-12-316,922,274shares365
2012-01-01 to 2012-12-316,981,527shares366

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2014-10-01 to 2014-12-310.29USD/shares92
2014-01-01 to 2014-12-310.72USD/shares365
2014-07-01 to 2014-09-300.21USD/shares92
2014-04-01 to 2014-06-300.09USD/shares91
2014-01-01 to 2014-03-310.12USD/shares90
2013-10-01 to 2013-12-310.27USD/shares92
2013-01-01 to 2013-12-310.83USD/shares365
2013-07-01 to 2013-09-300.19USD/shares92
2013-04-01 to 2013-06-300.16USD/shares91
2013-01-01 to 2013-03-310.21USD/shares90
2012-01-01 to 2012-12-310.47USD/shares366

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2014-10-01 to 2014-12-310.27USD/shares92
2014-01-01 to 2014-12-310.66USD/shares365
2014-07-01 to 2014-09-300.2USD/shares92
2014-04-01 to 2014-06-300.08USD/shares91
2014-01-01 to 2014-03-310.11USD/shares90
2013-10-01 to 2013-12-310.25USD/shares92
2013-01-01 to 2013-12-310.76USD/shares365
2013-07-01 to 2013-09-300.17USD/shares92
2013-04-01 to 2013-06-300.15USD/shares91
2013-01-01 to 2013-03-310.19USD/shares90
2012-01-01 to 2012-12-310.43USD/shares366

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2014-01-01 to 2014-12-312,386,707USD365
2013-01-01 to 2013-12-312,684,816USD365
2012-01-01 to 2012-12-312,174,054USD366

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2014-01-01 to 2014-12-3121,416USD365
2013-01-01 to 2013-12-31111,636USD365
2012-01-01 to 2012-12-31228,485USD366

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2014-10-01 to 2014-12-312,869,051USD92
2014-01-01 to 2014-12-316,999,359USD365
2014-07-01 to 2014-09-302,122,379USD92
2014-04-01 to 2014-06-30875,659USD91
2014-01-01 to 2014-03-311,132,270USD90
2013-10-01 to 2013-12-312,575,607USD92
2013-01-01 to 2013-12-317,944,461USD365
2013-07-01 to 2013-09-301,738,501USD92
2013-04-01 to 2013-06-301,563,685USD91
2013-01-01 to 2013-03-312,066,668USD90
2012-01-01 to 2012-12-315,120,495USD366

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2014-12-3125,148,810USD
At 2013-12-3118,273,461USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2014-12-31671,212USD
At 2013-12-31781,545USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2014-12-312,987,047USD
At 2013-12-315,004,418USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2014-01-01 to 2014-12-31829,613USD365
2013-01-01 to 2013-12-31674,874USD365
2012-01-01 to 2012-12-311,034,647USD366

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2014-01-01 to 2014-12-311,263,512USD365
2013-01-01 to 2013-12-311,484,416USD365
2012-01-01 to 2012-12-311,249,755USD366

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2014-12-316,730,622shares
At 2013-12-316,354,429shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2014-12-3125,059,458USD
At 2013-12-3120,951,796USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2014-12-31295,030USD
At 2013-12-31215,999USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2014-12-31210,847USD
At 2013-12-31326,519USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2014-12-311,078,771USD
At 2013-12-311,507,776USD
At 2012-12-311,573,050USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2014-01-01 to 2014-12-317,032,667USD365
2013-01-01 to 2013-12-317,970,663USD365
2012-01-01 to 2012-12-315,155,129USD366

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2014-01-01 to 2014-12-315,814,185USD365
2013-01-01 to 2013-12-315,038,363USD365
2012-01-01 to 2012-12-314,774,828USD366

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2014-01-01 to 2014-12-31247,097USD365
2013-01-01 to 2013-12-3164,323USD365
2012-01-01 to 2012-12-3164,190USD366

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2014-01-01 to 2014-12-311,150USD365
2013-01-01 to 2013-12-310USD365
2012-01-01 to 2012-12-310USD366

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2014-01-01 to 2014-12-3133,308USD365
2013-01-01 to 2013-12-3126,202USD365
2012-01-01 to 2012-12-3134,634USD366

Current income tax expense or benefit

Income tax expense or benefit for the period that is currently payable or refundable. It differs from cash taxes paid and from total tax expense.

PeriodValueUnitDays
2014-01-01 to 2014-12-311,957,703USD365
2013-01-01 to 2013-12-312,750,088USD365
2012-01-01 to 2012-12-31699,150USD366

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2014-01-01 to 2014-12-31429,004USD365
2013-01-01 to 2013-12-31-65,272USD365
2012-01-01 to 2012-12-311,474,904USD366

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2014-01-01 to 2014-12-31-2,017,371USD365
2013-01-01 to 2013-12-31-77,942USD365
2012-01-01 to 2012-12-311,845,443USD366

Inspect the source

Entity
BIOSPECIFICS TECHNOLOGIES CORP / CIK 0000875622
Captured
SEC response SHA-256
b1d443fa8a2de5e07d7cbcf40e33944d546011c718a394f04bbb863281862def

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000875622.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))